Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study

Journal:
The Lancet
Published:
Affiliations:
28
Authors:
30
Institutions Authors Share
AnaCardio, Sweden
5.333333
0.18
Karolinska University Hospital, Sweden
4.000000
0.13
University Medical Center Groningen (UMCG), RUG, Netherlands
3.000000
0.10
Sahlgrenska University Hospital (SU), GU, Sweden
1.000000
0.03
King's College Hospital, King's College Hospital NHS Foundation Trust, United Kingdom (UK)
1.000000
0.03
Golden Jubilee National Hospital, NHSGGC, United Kingdom (UK)
1.000000
0.03
University Medical Center Utrecht (UMC Utrecht), Netherlands
1.000000
0.03
University of Dundee, United Kingdom (UK)
1.000000
0.03
University of Trieste (UNITS), Italy
1.000000
0.03
Erasmus University Medical Center (Erasmus MC), Netherlands
1.000000
0.03
Northwestern University (NU), United States of America (USA)
1.000000
0.03
University of Michigan (U-M), United States of America (USA)
1.000000
0.03
Brigham and Women's Hospital (BWH), United States of America (USA)
1.000000
0.03
Helsinn Healthcare S.A., Switzerland
1.000000
0.03
University of Glasgow, United Kingdom (UK)
1.000000
0.03
Maastricht University Medical Center+ (Maastricht UMC+), Netherlands
0.500000
0.02
Maastricht University (UM), Netherlands
0.500000
0.02
Skåne University Hospital in Lund, SUS, Sweden
0.500000
0.02
Lund University (LU), Sweden
0.500000
0.02
Amsterdam UMC, Location VUmc, Netherlands
0.500000
0.02
Amsterdam Cardiovascular Sciences, Netherlands
0.500000
0.02
San Raffaele Scientific Institute, Italy
0.500000
0.02
Vita-Salute San Raffaele University (UniSR), Italy
0.500000
0.02
National Heart Centre Singapore (NHCS), Singapore
0.500000
0.02
Duke-NUS Medical School, Singapore
0.500000
0.02
Danderyd Hospital (DS), Sweden
0.333333
0.01
Karolinska Institute (KI), Sweden
0.333333
0.01